Innovative Therapies for Children with Cancer in Europe

2013

Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study.

A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study.

Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: A European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study

Angela Di Giannatale a,1, Nathalie Dias-Gastellier a,1, Annick Devos b,1, Kieran Mc Hugh c,1, Ariane Boubaker d,1, Frederic Courbon e,1, Arnaud Verschuur f,1, Ste´phane Ducassoul g,1, Katty Malekzadeh a,1, Michela Casanova h,1, Loredana Amoroso i,1, Pascal Chastagner j,1, Christian M. Zwaan b,1, Caroline Munzer k,1, Isabelle Aerts n,1, Judith Landman-Parker l,1, Riccardo Riccardi m,1, Marie-Cecile Le Deley a,1, Birgit Geoerger a,1, Herve´ Rubie k,⇑,1

EJC in press. 

Dasatinib in Children and Adolescents with Relapsed or Refractory Leukemia: Results of the CA180018 Phase I Dose-Escalation Study of the ‘Innovative Therapies for Children with Cancer’ Consortium. 

C. Michel Zwaan, Carmelo Rizzari, Francoise Mechinaud, Donna L. Lancaster, Thomas Lehrnbecher, Vincent H.J. van der Velden, B. Berna Beverloo, Monique L. den Boer, Rob Pieters, Dirk Reinhardt, Michael Dworzak, Julie Rosenberg, George Manos, Shruti Agrawal, Lewis Strauss, Andre´ Baruchel, and Pamela R. Kearns. J Clin Oncol, 2013 May 28